These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Shomali W; Gotlib J Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368 [TBL] [Abstract][Full Text] [Related]
9. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Tefferi A; Gotlib J; Pardanani A Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713 [TBL] [Abstract][Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771 [TBL] [Abstract][Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676 [TBL] [Abstract][Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Shomali W; Gotlib J Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850 [TBL] [Abstract][Full Text] [Related]
13. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. Pardanani A; Verstovsek S Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976 [TBL] [Abstract][Full Text] [Related]
14. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563 [TBL] [Abstract][Full Text] [Related]